LNP formulations produce strong immune responses, data shows
Drug Discovery World
FEBRUARY 15, 2024
etherna’s Vice President, Technology & Innovation, Stefaan De Koker described the paper as a “landmark” for the company and its technology.
Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class
pharmaphorum
MAY 11, 2021
Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. The post Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class appeared first on.
RNA 
98
98 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Biotech company raises $30M to target RNA modifying enzymes
Drug Discovery World
DECEMBER 16, 2022
The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . STC-15 triggers both direct cytotoxic and immune response-based efficacy mechanisms in solid tumour and leukaemia models.
RNA 52
52 
AstraZeneca makes a big RNA play, teaming up with VaxEquity
pharmaphorum
SEPTEMBER 23, 2021
AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. The company sees its deal with VaxEquity as going well beyond COVID-19, extending into other vaccines as well as therapeutic drugs.
RNA 52
52 
How transcriptomics is driving drug discovery
Drug Discovery World
FEBRUARY 13, 2023
Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. DDW: Could you explain the process of transcriptomics?
RNA 52
52 
Positive initial results for srRNA rabies vaccine
Drug Discovery World
FEBRUARY 19, 2024
At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus. Preliminary data show that the surrogate metric of protection (RVNA≥0.5)
Vaccination 52
52 
This week in drug discovery (8-12 January)
Drug Discovery World
JANUARY 12, 2024
This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. The post This week in drug discovery (8-12 January) appeared first on Drug Discovery World (DDW).
Drugs 52
52 
Rome Therapeutics raises $77m for junk DNA-targeting drugs
pharmaphorum
SEPTEMBER 14, 2021
Most drug discovery programmes target the roughly 2% of the human genome which encodes for protein. When cells are healthy most sequences lie dormant but, in disease or stress situations, the DNA can be activated to create virus-like RNA. That muffles the immune system response and allows the cancer to grow.
DNA 52
52 
Genetic profiling of Lyme disease could bring new therapeutic targets
Drug Discovery World
NOVEMBER 17, 2022
The study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease. . As part of the study, RNA sequencing was conducted using blood samples from 152 patients with symptoms of post-treatment Lyme disease to measure their immune response. .
Genetics 52
52 
Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical
Delveinsight
SEPTEMBER 23, 2021
Boehringer Ingelheim acquires Abexxa Biologics for precision most cancers drug pipeline. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising. Stafford and co.
RNA 61
61 
Gene Therapy and Pharmacokinetics
Camargo
JULY 27, 2021
When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.
Gene Therapy 238
238 
Roche pays $200m for Vaccibody’s cancer vaccine drug
pharmaphorum
OCTOBER 2, 2020
Genentech, which is already well established as a player in cancer immunotherapy with its PD-L1 class drug Tecentriq (atezolizumab) , will be responsible for development and marketing thereafter. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology.
Vaccination 59
59 
Partnership hopes to improve large-scale exosome production
Drug Discovery World
NOVEMBER 30, 2022
Exosomes are emerging as an effective, non-viral chassis for genetic medicines, as they are non-toxic, efficient at delivering RNA cargoes into cells and able to do so without eliciting an immune response. . The post Partnership hopes to improve large-scale exosome production appeared first on Drug Discovery World (DDW).
Production 52
52 
World AIDS Day 2023: New and Promising Treatments for HIV/AIDS
XTalks
NOVEMBER 30, 2023
New FDA-Approved Treatments For HIV HIV treatment involves the administration of combined antiretroviral therapy (ART) to effectively suppress the viral load, maintain or enhance immune function and reduce the risk of opportunistic infections and cancers commonly associated with HIV. percent in the placebo group.
FDA Approval 111
111 
New strategy for COVID-19 prophylaxis?
The Pharma Data
MARCH 8, 2022
The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines. In the light of the further risk of pandemics in the future, however, there remains need for direct antiviral drugs and treatments. Camouflage protects virus from immune system.
BioNTech buys UK-based AI startup InstaDeep in £562m deal
pharmaphorum
JANUARY 10, 2023
Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.
Vaccination 116
116 
Cash round sets up trial of InteRNA’s microRNA for cancer
pharmaphorum
FEBRUARY 9, 2021
million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.
Trials 59
59 
STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug
STAT News
MARCH 6, 2023
Cambridge-based Moderna recently reported encouraging results from a study of another type of personalized cancer vaccine it developed with the pharmaceutical giant Merck; it uses messenger RNA technology to target advanced melanoma. But more work remains before personalized vaccines can be greenlighted.
Vaccination 98
98 
mRNA universal influenza vaccine enters clinical trials
Drug Discovery World
MAY 18, 2023
This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response. Both vaccines use a specific portion of a flu protein, hemagglutinin (HA), to induce a broad immune response against influenza.
Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine
Delveinsight
AUGUST 26, 2021
Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. Datavant inks real-world data partnership with Real Chemistry.
Vaccination 98
98 
Personalised mRNA cancer vaccine prolongs survival in melanoma
Drug Discovery World
APRIL 16, 2023
Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.
Vaccination 52
52 
BioNTech to deliver prestigious lecture on mRNA
Drug Discovery World
JULY 26, 2022
Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The post BioNTech to deliver prestigious lecture on mRNA appeared first on Drug Discovery World (DDW).
Vaccination 52
52 
Investment fuels AI-driven development of breakthrough genomic medicines
pharmaphorum
OCTOBER 12, 2022
Having spent 10 years working in the genomics field, Del Bourgo noticed manufacturers spending extensive resources on drug development without harnessing the transformative power of data. The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells.
Genome 105
105 
Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry
Roots Analysis
OCTOBER 30, 2023
In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.
RNA 40
40 
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
The Pharma Data
DECEMBER 3, 2020
Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.
Vaccination 52
52 
CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
pharmaphorum
NOVEMBER 2, 2022
The promise in the self-assembling RNA technology lies in its potential to achieve a strong immune response using a lower dose of antigen than the current generation of mRNA shots, although it is generally a larger molecule and may be more challenging to deliver.
Vaccination 52
52 
Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
The Pharma Data
JULY 18, 2021
Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.
AstraZeneca COVID-19 Vaccine Shows Good Results in Late Trials
The Pharma Data
DECEMBER 8, 2020
. “In future analyses, with more data included as it becomes available, we will investigate differences in key subgroups such as older adults, various ethnicities, doses, timing of booster vaccines, and we will determine which immune responses equate to protection from infection or disease.” © 2020 HealthDay.
Vaccination 52
52 
World RNA Day: What impact RNA it had on drug discovery?
Drug Discovery World
AUGUST 1, 2023
1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.
RNA 52
52 
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
The Pharma Data
JANUARY 31, 2021
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.
Strong immune responses seen in adults of all ages
The Pharma Data
MAY 17, 2021
The drug companies had hoped to have regulatory approval for their jab in the first half of this year, but interim results from a Phase 1/2 study, released in December 2020, had shown an “insufficient” ? In addition to the collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio.
Months of Work Hang in the Balance as Moderna’s COVID-19 Vaccine Awaits AdComm Vote
The Pharma Data
DECEMBER 16, 2020
Food and Drug Administration (FDA) advisory panel in regard to the COVID-19 vaccine from Moderna. The Moderna vaccine is similar to Pfizer and BioNTech’s vaccine in the sense that they both use an approach utilizing messenger RNA (mRNA). Boumen Japet/Shutterstock. A critical vote is set to take place today amongst those on a U.S.
Vaccination 52
52 
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
The Pharma Data
JANUARY 31, 2021
Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Food and Drug Administration (FDA).
Vaccination 52
52 
Keeping tabs on Covid-19: UK firm tests oral delivery of Covid-19 vaccine and Novavax aims to distribute 51 million vaccines to Australia
The Pharma Data
JANUARY 22, 2021
As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.
Vaccination 52
52 
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
The Pharma Data
DECEMBER 10, 2020
The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.
Vaccination 52
52 
Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)
The Pharma Data
OCTOBER 25, 2020
The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. 26, 2020 11:00 UTC. CAMBRIDGE, Mass.–(
Vaccination 52
52 
What Innovative Treatments For Metastatic Breast Cancer are being developed?
Find Me Cure
OCTOBER 13, 2019
Drugs and therapies under study are our hope for the future of healthcare, so taking the time to learn more about them is an investment in your future health as well as the background education you need to make informed decisions about your treatment. Neratinib and tucatinib are such inhibitors being studied in metastatic breast cancer. .
Development 52
52 
Lab to jab in 100 days: manufacturing flexibility for future rapid responses
Pharmaceutical Technology
NOVEMBER 22, 2022
Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. When an mRNA vaccine is administered, a patient’s body produces that protein to prompt a desired immune response. million in funding to support this work.
Manufacturing 130
130 
Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021
The Pharma Data
JULY 6, 2021
Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year. FDA for ITP.
Protein 52
52 
Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?
Delveinsight
DECEMBER 13, 2020
alcohol, certain drugs) and autoimmune diseases can also cause hepatitis. Interferons are naturally occurring proteins in the body; recombinant IFNa is the protein-based drug that works to mobilize the body’s natural immune system to fight disease. Both drugs resulted in inhibition of HCV replication.
Genotype 52
52 
The challenges and trends of cell & gene therapies
Drug Discovery World
SEPTEMBER 6, 2022
There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 million price point per dose. Despite this the industry is still expanding.
Gene Therapy 52
52 
FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
The Pharma Data
DECEMBER 18, 2020
Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. SILVER SPRING, Md. ,
Vaccination 52
52 
The Future of Vaccine Development
VirTrial
OCTOBER 25, 2023
Despite well-constructed and rigorous clinical trials looking at the vaccines, there were those that would not be immunized leading to further death and spread of the disease. The studies reported the outcomes of thousands of volunteers who participated in the clinical trials which showed safety and efficacy of the vaccine.
Vaccination 52
52 
National Cancer Research Month: Celebrating drug discovery innovation
Drug Discovery World
MAY 30, 2023
From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. Immunopheresis is a ‘subtractive therapy,’ in contrast to alternative drugs that constitute ‘additive’ therapies.
Research 52
52 
Let's personalize your content